BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
69.37
+1.22 (1.79%)
At close: Oct 27, 2026, 4:00 PM EDT
69.59
+0.22 (0.32%)
Pre-market: Oct 28, 2026, 7:16 AM EDT
BridgeBio Pharma Stock Forecast
Stock Price Forecast
According to 23 analysts polled by S&P Global, BridgeBio Pharma stock has a consensus rating of "Strong Buy" and an average price target of $107.81. The average 1-year stock price forecast is 55.41% higher than the current stock price, while the lowest is $80 (+15.32%) and the highest is $156 (+124.88%).
Price Target: $107.81 (+55.41%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 16 | 14 | 14 | 14 | 15 |
| Buy | 6 | 6 | 6 | 5 | 5 | 6 |
| Hold | 2 | 2 | 2 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 22 | 22 | 22 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $110 | Buy | Reiterates | $110 | +58.57% | Oct 26, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $87 | Buy | Maintains | $87 | +25.41% | Oct 21, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $115 → $120 | Buy | Maintains | $115 → $120 | +72.99% | Oct 19, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $104 → $102 | Buy | Reiterates | $104 → $102 | +47.04% | Oct 19, 2026 |
| Citi | Citi | Hold Maintains $94 → $91 | Hold | Maintains | $94 → $91 | +31.18% | Oct 19, 2026 |
Financial Forecast
Revenue This Year
1.04B
from 502.08M
Increased by 107.07%
Revenue Next Year
1.67B
from 1.04B
Increased by 60.44%
EPS This Year
-2.62
from -3.78
EPS Next Year
-0.22
from -2.62
EPS and Forward PE are based on non-GAAP adjusted numbers.